Xiaohui Hu

Xiaohui Hu

Auto-generated profile, based on publicly available information

Xiaohui Hu

School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi 330031, People's Republic of China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Acta Crystallographica Section F Structural Biology Communications
Verified
Journal Article
Closed access
PDF file
HGHongxia Gao
Hongxia Gao
YZYuting Zhang
Yuting Zhang
HJHaihai Jiang
Haihai Jiang
XHXiaohui Hu
Xiaohui Hu
XZXuelan Zhou
Xuelan Zhou
JZJin Zhang
Jin Zhang

13 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
XZXuelan Zhou
Xuelan Zhou
FZFangling Zhong
Fangling Zhong
CLCheng Lin
Cheng Lin
XHXiaohui Hu
Xiaohui Hu
YZYan Zhang
Yan Zhang
JZJin Zhang
Jin Zhang
M pro is of considerable interest as a drug target in the treatment of COVID-19 since the proteolytic activity of this viral protease is essential for viral replication. Here we report the first insight of the structure M pro for SARS-CoV-2 in the inactive conformation under conditions close to the physiological state (pH 7.5) to an overall resolution of 1.9 Å. The comparisons of M pro in different states reveal that substrate binding site and the active site are more flexible in the inactive conformation than that in the active conformations. Notably, compared with the active conformation of the apo state structure in pH7.6 of SARS, the SARS-CoV-2 apo state is in the inactive conformation under condition close to physiological state (pH7.5). Two water molecules are present in the oxyanion hole in our apo state structure, whereas in the ligand-bound structure, water molecular is absence in the same region. This structure provides novel and important insights that have broad implications for understanding the structural basis underlying enzyme activity, and can facilitate rational, structure-based, approaches for the design of specific SARS-CoV-2 ligands as new therapeutic agents.